Microsatellite Stable Clinical Trials

20 recruitingLast updated: June 17, 2026

There are 20 actively recruiting microsatellite stable clinical trials across 10 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Houston, Texas, United States, New York, New York, United States, Pittsburgh, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Microsatellite Stable Trials at a Glance

20 actively recruiting trials for microsatellite stable are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Houston, New York, and Pittsburgh. Lead sponsors running microsatellite stable studies include Fudan University, National Cancer Institute (NCI), and Dan Feng.

Browse microsatellite stable trials by phase

Treatments under study

About Microsatellite Stable Clinical Trials

Looking for clinical trials for Microsatellite Stable? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Microsatellite Stable trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Microsatellite Stable clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 2

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Locally Advanced Rectal AdenocarcinomaMicrosatellite Stable Rectal Carcinoma
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT06843434
Recruiting
Phase 1Phase 2

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)42 enrolled23 locationsNCT05691491
Recruiting
Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled11 locationsNCT07540572
Recruiting
Phase 2

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Advanced Microsatellite Stable Colorectal Cancer
Gilead Sciences170 enrolled5 locationsNCT07527858
Recruiting
Phase 1Phase 2

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb1,109 enrolled47 locationsNCT04895709
Recruiting
Phase 1

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

First-line TreatmentMetastatic Colorectal Cancer (CRC)Phase 1+4 more
M.D. Anderson Cancer Center41 enrolled1 locationNCT07500298
Recruiting
Phase 1Phase 2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8Metastatic Microsatellite Stable Colorectal CarcinomaRefractory Microsatellite Stable Colorectal Carcinoma
National Cancer Institute (NCI)39 enrolled8 locationsNCT06654037
Recruiting
Phase 3

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

Rectal CancerpMMR (Microsatellite Stable Rectal Cancer)
Sun Yat-sen University556 enrolled1 locationNCT07528209
Recruiting
Phase 2

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Colorectal, CancerBRAF V600ESintilimab+4 more
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109
Recruiting
Phase 1

A Study of VET3-TGI in Patients With Solid Tumors

Cervical CancerNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma+10 more
KaliVir Immunotherapeutics60 enrolled7 locationsNCT06444815
Recruiting
Phase 1Phase 2

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Metastatic Microsatellite Stable Colorectal Carcinoma
Dan Feng24 enrolled1 locationNCT07281716
Recruiting
Phase 2

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Stingray Therapeutics70 enrolled6 locationsNCT06589440
Recruiting
Phase 1

A Study of NX-1607 in Adults With Advanced Malignancies

Gastric CancerNon-small Cell Lung Cancer (NSCLC)Cervical Cancer+11 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674
Recruiting
Phase 2

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

Colorectal, CancerMicrosatellite Stable Colorectal Carcinoma
Fudan University25 enrolled1 locationNCT05771181
Recruiting
Phase 2

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1,Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

Microsatellite Stable Metastatic Colorectal Cancer
Fudan University116 enrolled1 locationNCT06841159
Recruiting
Phase 2

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Colorectal Cancer MetastaticMicrosatellite Stable Colorectal CarcinomaRefractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS36 enrolled2 locationsNCT06522919
Recruiting
Phase 2

Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

Microsatellite Stable Metastatic Colorectal Cancer
Fudan University108 enrolled1 locationNCT05963490
Recruiting
Phase 2

Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

Microsatellite Stable Metastatic Colorectal Cancer
Fudan University96 enrolled1 locationNCT06525428
Recruiting
Phase 2

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal CancerRAS MutationCadonilimab+1 more
Fudan University53 enrolled1 locationNCT06218810